Navigation Links
Singulex Announces Presentation on Monitoring of Cardiac Biomarker to Assess Transient Myocardial Ischemia at the American Heart Association Scientific Sessions
Date:11/4/2007

ORLANDO, Fla., Nov. 4 /PRNewswire/ -- Singulex Inc. announced today that its technology will be highlighted in an oral presentation (#3108) at the American Heart Association Scientific Sessions on Wednesday, November 7 at 11:15 a.m. in West F1. The presentation is entitled "Single Molecule Troponin Detection to Assess for Transient Myocardial Ischemia" by Marc Sabatine, M.D., M.P.H. and David Morrow, M.D., M.P.H.

Dr. Sabatine is an associate physician in the Cardiovascular Medicine Division at Brigham and Women's Hospital (BWH), an investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, and an assistant professor of medicine at Harvard Medical School. Dr. Sabatine's research focuses on the diagnosis and treatment of acute coronary syndromes, with a particular interest in using biomarkers, genetic epidemiology, and proteomics for risk stratification. His research endeavors in those fields are supported by several grants from the National Institutes of Health. Dr. Sabatine has authored over 100 original research articles, reviews, editorials, and book chapters and serves as a manuscript reviewer for several major medical journals. Dr. Sabatine has been awarded a Howard Hughes Medical Institute Research Fellowship, an ACC Cardiology Fellowship, and the ACC Young Investigator Award. He is board certified in Internal Medicine and Cardiology and is a member of the American Heart Association and a Fellow of the American College of Cardiology.

Dr. Morrow is assistant professor of medicine at Harvard Medical School, in the division of cardiovascular medicine at BWH. He was instrumental in the development of the TIMI Biomarker Program at BWH, and his research at TIMI focuses on risk stratification and the management of acute coronary syndromes. Dr. Morrow sits on the National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines Committee on Biochemical Cardiac Markers and leads the clinical section on ACS. He is on the editorial boards of American Heart Journal, Circulation, Clinical Chemistry, and the Journal of the American College of Cardiology and is a Continuing Medical Education editor for Circulation. Dr. Morrow is also the editor of "Cardiovascular Biomarkers: Pathophysiology and Disease Management" and serves on the Program Committee for the American Heart Association Council on Clinical Cardiology. In addition to being a frequent lecturer, Dr. Morrow has more than 100 original reports, reviews, editorials, book chapters, and electronic publications in his areas of expertise.

About Singulex

Singulex develops and commercializes innovative technology solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex develops customized biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers in a variety of biological samples with extreme sensitivity and accuracy. Singulex is currently conducting several pilot studies with academic and molecular diagnostic partners to validate the company's commercial digital molecule detection platform, the Erenna(TM) Immunoassay System. Singulex's research and development facilities are located at the Center for Emerging Technologies in St Louis, Missouri, and the company's commercial operations are based in Hayward, California. To learn more about Singulex, please visit us at http://www.singulex.com.


'/>"/>
SOURCE Singulex Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... Drs. Steven Crandall, Karen Johnson ... in Pittsburgh, PA, and Upper St. Clair, PA, without a referral. The doctors address ... the health of the temporomandibular joint and facial muscles that support it. , ...
(Date:6/28/2017)... ... , ... Eating disorders have the highest mortality rate of any mental illness ... as a direct result from an eating disorder in the U.S. As the rate ... Foundation meets this challenge by offering what has become the leading certification program for ...
(Date:6/28/2017)... ... June 28, 2017 , ... Park Systems , a leader in Atomic ... SEMICONWest attendees and Park customers on July 11, 2017 from 12-2pm at the ... Chairman & CEO of Park Systems, and Prof. Krishna Saraswat , Rickey/Nielsen Professor ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers Insurance Agency, ... in northern Virginia and DC, is announcing a cooperative charity event in conjunction ... and other disorders that lead to memory impairment. , The Insight Memory Care ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands that ... they can trust the sponsor to pay them correctly and on time. As the ... establish payment strategies that encourage sites to work on their studies. , At a ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... BELL, Pa. , June 1, 2017 ... (PRN) and Veterinarian Recommended Solutions (VRS), and KD Pharma ... investment in Nutriceutical Holdings by KD Pharma Group. KD ... Holdings with the option to acquire the entire company. ... partner in KD. They are committed to growing the ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
(Date:5/26/2017)... May 25, 2017  In response to the opioid ... Direct Relief is working with Pfizer to make up ... no cost to community health centers, free and charitable ... "Pfizer has a long-standing commitment to ... ensuring patient safety through educational activities," said Caroline ...
Breaking Medicine Technology: